R726L androgen receptor mutation is uncommon in prostate cancer families in the united states by Gruber, Stephen B. et al.
The Prostate 54:306 ^309 (2003)
R726LAndrogenReceptorMutation IsUncommonin
ProstateCancer Families in theUnited States
Stephen B. Gruber,1,3 Hong Chen,1 Lynn P. Tomsho,1 Nana Lee,1
Erin E. Perrone,2 and Kathleen A. Cooney1,2,4*
1Departmentof InternalMedicine,UniversityofMichiganMedical School, Ann Arbor,Michigan
2DepartmentofUrology,UniversityofMichiganMedical School, Ann Arbor,Michigan
3Departmentof Epidemiology,UniversityofMichigan Schoolof PublicHealth, Ann Arbor,Michigan
4Departmentof Veterans AffairsMedical Center, Ann Arbor,Michigan
BACKGROUND. A mutation in the androgen receptor (AR) gene, namely AR R726L, was
described in 2% of Finnish men with sporadic or familial prostate cancer and was associated
with an approximately sixfold increased risk of prostate cancer. We set out to determine the
incidence of this mutation in a sample of men with either early-onset and/or familial prostate
cancer in the United States.
METHODS. Five hundred forty-eight men with prostate cancer from 411 unrelated families
participating in the University of Michigan Prostate Cancer Genetics Project (PCGP) were
studied. Allele-specific oligonucleotide hybridization was used to detect the presence of the
AR R726L mutation in germline DNA.
RESULTS. None of the 548 prostate cancer patients studied, including 513 White, 29 African
American, 3Asian, and 3Hispanicmen,were found to carry theARR726L allele. Therefore, the
prevalence of this allele is significantly less than that observedamongFinnishmenwithprostate
cancer (Fisher’s exact test, P¼ 0.002).
CONCLUSIONS. The AR R726L allele does not account for a significant proportion of early-
onset and/or familial prostate cancer in the United States. Prostate 54: 306–309, 2003.
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INTRODUCTION
The observation that prostate cancer aggregates in
families has led investigators to search for germline
mutations that may increase the susceptibility to
prostate cancer (see review [1]). Since the relative risk
attributed to having a brother with prostate cancer is
twice as high as that conferred by an affected father,
some investigators have suggested that there may be
X-linked and/or recessive prostate cancer loci [2]. The
androgen receptor (AR) gene (OMIM *313700), located
at Xq11-12, has been proposed as a candidate prostate
cancer susceptibility gene. However, the AR gene is
approximately 50 cM from the major HPCX candidate
region, and family based linkage studies have not
demonstrated linkage to the AR gene [3].
Recently,Mononen et al. [4] reported that a germline
mutation in the AR gene, specifically R726L in exon E,
occurs in approximately 2% of Finnish men with pro-
state cancer. This mutation was observed in a similar
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frequency in men with both familial and sporadic
prostate cancer, but it was detected in only 0.33% of
AR alleles among healthy blood donors. Overall, an
approximately sixfold increased risk of prostate cancer
was attributed to the R726L substitution (OR¼ 5.8, 95%
CI¼ 1.6–21.2). In 11 out of 13 men who carried the
mutation, the R726L substitution occurred in an AR
allele containing 26 CAG repeats suggesting the
presence of a founder allele in the Finnish population.
The University of Michigan Prostate Cancer Gene-
tics Project (PCGP) is a family-based study that was
established to determine the molecular basis for in-
herited prostate cancer susceptibility. We set out to
determine the potential contribution of the AR R726L
mutation to familial prostate cancer in an ethnically
diverse population from the US.
METHODS
Study Population
Five hundred forty-eight men with histologically
confirmed prostate cancer from 411 unrelated families
who are participants in the University of Michigan
PCGP were included in the study. Men with prostate
cancer are eligible to enroll in the PCGP if they were
diagnosed age 55 and/or if they have 1 living first-
or second-degree relative with prostate cancer. Writ-
ten, informed consent was obtained from each patient,
and the study protocol was approved by the Institu-
tional Review Board of the University of Michigan.
Two hundred seventy of the men were from families
with two or more affected men with prostate cancer;
these men were described previously in an analysis of
AR CAG length [5]. All diagnoses of prostate cancer
were confirmed by pathology reports or review of
medical records.
LaboratoryMethods
GenomicDNAwas isolated fromwhole blood using
a commercially available kit (PuregeneDNAextraction
kit; Gentra Systems, Inc., Research Triangle, NC).
Allele-specific oligonucleotide (ASO) hybridization
was performed as previously described [4]. Male geno-
mic DNA containing the AR R726L mutation was
used as a hybridization control (kindly provided by
N. Mononen). AR CAG repeat length was measured
as previously reported.
StatisticalMethods
Contingency tables were analyzed using Fisher’s
exact test, and all P-values are reported as two-tailed
tests. All analyses were conducted using SAS version
8.00 (SAS Institute, Inc., Cary, NC).
ProteinModeling
Diagrams of the three-dimensional structure of the
ligand-binding domain (LBD) of the human androgen
receptor protein (hAR) were built using RIBBONS
2.0 [6] based on the coordinates of the hAR LBD-R1881
complex [7] available through the Protein Data Bank
(PDB ID 1e3g, http://www.rcsb.org) [8]. The hARLBD
consists of 262 amino acids encompassing amino acids
657 through 919 of the full-length AR.
RESULTS
In this study, germline DNA was analyzed from
a total of 548 men with prostate cancer, including
411 unrelated probands with prostate cancer. The
average age of prostate cancer diagnosis in the men
reported here was 61.0 years (SD¼ 9.6, range 36–93).
Forty percent of probands were diagnosed  age 55.
Although the majority of participants described them-
selves as white and not of Hispanic origin, our sample
included 29 African American men, 3 Asian men, and
3 Hispanic men.
Using ASO hybridization, none of the 548 alleles
analyzed were shown to contain the R726L mutation
(Fig. 1). Therefore, the prevalence of the AR R726L
mutation among either the entire set of 548 US men
with prostate cancer or the 411 probands was sig-
nificantly less than that reported in Finnish men with
prostate cancer (Table I, Fisher’s exact test, P< 0.0001
and P¼ 0.003, respectively). When the PCGP probands
were restricted to those diagnosed at or before age 55,
the prevalence of the AR R726L substitution in men
with prostate cancer was also significantly less than
that detected in the Finnishpopulation (Table I, Fisher’s
exact test, P¼ 0.035). Furthermore, there was a sig-
nificant difference in the incidence of the R726L muta-
tion between white men with prostate cancer from the
PCGP and Finnish prostate cancer cases (Fisher’s exact
test, P¼ 0.002).
DISCUSSION
The AR R726L mutation is an interesting candidate
prostate cancer susceptibility allele, and previous func-
tional studies have demonstrated that this substitution
results in an AR that is activated by both testosterone
and estradiol [9]. Three-dimensional modeling of hAR
LBD in complex with the ligand metribolone (R1881)
[7] shows the side chain of R726 protruding out into the
surrounding milieu (Fig. 2). Since the location of this
amino acid is at a distance from the ligand-binding
site, the R726L substitution is unlikely to directly alter
binding affinity. The R726L polymorphism is also
not predicted to have a significant impact on overall
structure. However, substitution of a nonpolar amino
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acid (leucine) for a basic amino acid (arginine) may
alter AR surface charge and consequently influence
other molecular interactions, such as with coactivators
of receptor action.
Exon 1 of the AR gene contains a highly poly-
morphic trinucleotide (CAG) repeat sequence, and
shorter AR CAG repeats have been suggested to
increase the risk of prostate cancer in some studies
[10–12]. This relationship is biologically plausible since
in vitro experiments reveal that AR alleles with fewer
CAG repeats result in an AR with increased transacti-
vation function [13]. In the Mononen report, however,
11/13 of the Finnish prostate cancer patients with the
AR R726Lmutation also had an AR CAG repeat length
of 26 consistent with linkage disequilibrium between
the AR CAG repeat and the R726L mutation [4]. Since
short rather than long CAG repeats have been asso-
ciated with prostate cancer incidence, the CAG repeat
of 26 is unlikely to be contributing to the risk of prostate
cancer associated with this Finnish AR allele.
In our study, we considered two possible hy-
potheses. First, the AR R726L allele could be a founder
allele in the US in which case the mutation should
be detected on an AR allele containing a CAG repeat
length of 26. Alternatively, the AR R726L mutation
could be occurring de novo in the population, and thus
the R726Lmutation should be detected on an AR allele
with any number of CAG repeats. The most common
number of CAG repeats in Caucasian men with
prostate cancer in the US is 21, and alleles with more
than 25 CAG repeats or fewer than 19 repeats are
relatively uncommon [11]. Since we failed to detect
the R726L mutation in our study population, we
reviewed our data with regard to AR CAG length that
was available from a subset of themen in our report [5].
AlthoughAR alleles with 26 CAG repeats are relatively
TABLE I. Prevalence of the R726L Androgen Receptor Mutation in US Prostate Cancer
Patients
Genotype
N R726L Wild Type %
University of Michigan PCGP 548 0 548 0
White (not Hispanic origin) 513 0 513 0
African American 29 0 29 0
Asian or Pacific Islander 3 0 3 0
Hispanic 3 0 3 0
University of Michigan PCGP
probands
411 0 411 0
Probands dx 55 163 0 163 0
Probands dx> 55 248 0 248 0
Finlanda 1,302
Sporadic prostate cancer 418 8 410 1.91
Familial prostate cancer 106 2 104 1.92
Healthy blood donors 900b 3 897 0.33
aData from Mononen et al. [4].
bResults from 656 male and 122 female, healthy, anonymous blood donors for a total of 900 X-
linked AR alleles examined.
Fig. 1. Allele-specific oligonucleotide (ASO) hybridization for
detecting theARR726Lsubstitution.Allwells containedDNAsam-
ples from men with prostate cancer participating in the Prostate
Cancer Genetics Project except well F10 which contained control
DNA from a male carrier of the AR R726L allele and wells F11and
F12,whichwerewaterblanks.Duplicateblotswerehybridizedwith
thewild-type oligonucleotide in thepanel labeledwild type orwith
theR726Loligonucleotidein thepanellabeledmutant.
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rare, at least 11 men in this study (from 11 unrelated
families) were shown to carry anAR allele containing a
CAG repeat length of 26.
The minimum number of independent AR alleles
in this data set is 411 taking into account familial
relationships. We found no evidence of the R726L
mutation in white men with prostate cancer from our
study of inherited prostate cancer susceptibility in
the US compared to Finnish cases. In addition, we
did not find the mutation in any of the African
American, Asian/Pacific Islander, or Hispanic men
with prostate cancer in our study (Table I). However
due to small sample sizes, our power was too low to
detect this mutation in any racial subgroup other than
white men.
CONCLUSIONS
Our data are consistent with the hypothesis that
the AR R726L allele is a founder prostate cancer allele
in Finland, and that this mutation does not account
for a significant proportion of early-onset and/or fami-
lial prostate cancer in the United States. These data also
suggest that population stratification remains an im-
portant methodological issue in studies of the genetic
epidemiology of prostate cancer.
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Fig. 2. RIBBONS 2.0 diagrams of the three-dimensional struc-
ture of hAR LBD-R1881.The basic residues H714, K717, R720, R726
are indicated in blue.The ligandmetribolone (R1881) is indicated in
green.
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